Proposed share consolidation; proposed capital Reduction; proposed share sub-division and proposed change in board lot size
Filed with HKEX · Stock code 858 · · 14 pages · English
Summary by 6ix AI
Extrawell Pharmaceutical Holdings Limited has proposed a series of transactions including a share consolidation, capital reduction, and share sub-division, along with a change in board lot size for trading purposes. The share consolidation aims to consolidate existing shares into fewer consolidated shares, while the capital reduction will adjust the par value of shares. These changes are intended to enhance the attractiveness of the shares to investors and comply with trading requirements set by the Stock Exchange. The company plans to hold a special general meeting for shareholders to approve these proposed transactions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Extrawell Pharmaceutical Holdings Limited on 6ix
Earlier from Extrawell Pharmaceutical
- List of directors and their roles and functions
- Appointment of executive director
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Further extension of long stop date in respect of proposed fourth amendments to the terms and conditions of the bonds
- Extrawell Pharmaceutical Holdings: Proposals for general mandates to issue new shares and buy back shares, re-election of retiring directors and notice of annual general meeting
Later from Extrawell Pharmaceutical
- Termination of the memorandum of understanding in relation to the possible sale of the convertible bonds
- Grant of share options to directors and connected transaction at subsidiary level in relation to the grant of share options to the service provider
Follow Extrawell Pharmaceutical into a list and get an email when it puts out news.
Follow Extrawell Pharmaceutical